Phase 2 N=38 Spondylitis Trial of Apremilast for Better Rheumatic Therapy
Ankylosing Spondylitis
Primary: Changes of Apremilast in Patients With AS, Changes in BASDAI Score From Baseline — -0.77; -1.59 units on a scale — p=0.139
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=490 Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis
Ankylosing Spondyloarthritis
Primary: Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16 — 36.6; 35.0; 32.5 Percentage of…
Phase 3 N=82 Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Number of Subjects With a Reduction in Signs and Symptoms as Measured by Assessments of Ankylosing Spondylitis (ASAS) 20 Response at Week 12 — 18; 12; 20; 32…
Phase 4 N=82 Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Normalized Net Incremental Area Under the Curve (AUC) for the Bath Ankylosing Spondylitis Disease Activities Index (BASDAI) Between Randomization and Week 12 — -19.79…
Phase 3 N=356 A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis
Spondylitis, Ankylosing
Primary: Assessment in Ankylosing Spondylitis 20 Responders at Week 14 — 17; 82; 84; 166 Participants — p=<0.001
Phase 4 N=566 Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20) — 287; 99 participants — p=<0.001
Phase 2 N=30 Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Percentage of Participants Who Achieved ASAS20 Response — 59.2; 24.5 Percentage
Phase 3 N=208 A Study of Golimumab in Participants With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Percentage of Participants Who Achieved at Least 20 Percent Improvement From Baseline in the Assessment of SpondyloArthritis International Society (ASAS 20) at Week 16…
Phase 2 N=187 A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis
Ankylosing Spondylitis (AS)
Primary: Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 14 — 25.5; 51.6 percentage of participants — p=<0.001
Phase 3 N=270 Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)
Ankylosing Spondylitis
Primary: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS)20 Response at Week 16 — 56.39; 29.41 Percentage of participants…
N/A N=55 Exercise Therapy Program in Ankylosing Spondylitis Patients
Ankylosing Spondylitis
Primary: FUNCTIONAL INDEX — 3.4; 4.3; 3.2; 4.5 units on a scale — p=0.13
Phase 3 N=315 Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Number of Responders With a Reduction of Signs and Symptoms of Ankylosing Spondylitis (AS) as Measured With ASAS International Working Group Response Criteria (ASAS 20)…
Phase 3 N=344 Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Number of Participants Meeting the Assessment of Spondyloarthritis International Society (ASAS) ASAS20 Response Criteria — 154; 35 participants — p=< 0.001
Phase 2 N=255 A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study — 92.9 percentage of participants
Phase 3 N=158 Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
Ankylosing Spondylitis · Axial Spondyloarthritis
Primary: Number of Participants Achieving the Assessment in Ankylosing Spondylitis (ASAS) Partial Remission Criteria at Week 28 — 65; 18; 40; 33 Participants
N/A N=80 Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel.
Ankylosing Spondylitis
Primary: Work Productivity and Activity Impairment Questionnaire - Ankylosing Spondylitis (WPAI-AS) Scale Scores at Baseline — 30.18; 49.09; 53.06; 63.29 Percentage of impairment
N/A N=147 Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing Spondylitis
Rheumatoid Arthritis · Bone Resorption · Ankylosing Spondylitis
Primary: Osteoclast Differentiation Ex-vivo — 8; 12; 11; 5 OC/mm2
N/A N=403 Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Ankylosing Spondylitis
Primary: Number of Participants With Adverse Drug Reactions — 101; 15 Participants
N/A N=1,685 Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Percentage of Participants Achieving Partial Remission at Week 26 — 19.0 percentage of participants
Phase 3 N=371 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Assessment of Responders for the SpondyloArthritis International Society / ASAS 20 Response — 59.7; 60.8; 28.7 % responders — p=<0.0001
Phase 2 N=207 Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Percentage of Participants Achieving 20 Percent (%) Improvement in Assessment of SpondyloArthritis International Society (ASAS) Score (ASAS 20) at Week 12 — 56.0; 63.0…
N/A N=152 Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy
Ankylosing Spondylitis
Primary: Percentage of Participants With Unchanged First Line Anti-TNF Treatment Up to Month 18 — 85.42 percentage of participants
Phase 4 N=108 Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain
Ankylosing Spondylitis
Primary: Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 20. — 34; 37 patients — p=0.6031
N/A N=201 Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients
Ankylosing Spondylitis
Primary: Frequency of Extra-Axial Manifestations (EAMs) of Interest — 46.27; 33.33; 2.99 Percentage of participants
Phase 3 N=1,015 A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
Spondylitis, Ankylosing
Primary: Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Naproxen — -31.23; -30.59 mm VAS
Phase 3 N=458 Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis
Ankylosing Spondyloarthritis
Primary: The Proportion of Participants Who Achieve an ASAS 20 Response (Assessment of SpondyloArthritis International Society Criteria) — 178; 56 Participants — p=<.0001
Phase 3 N=332 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16 — 22.5; 44.8 percentage of…
N/A N=132 Study Evaluating Predictors of Response in Patients With Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Percentage of Participants With a Clinical Response — 90.9; 9.1 percentage of participants
Phase 4 N=211 Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Proportion of Patients Who Achieved ASAS20 Response in the Pooled Secukinumab Group Compared With the Placebo Group at Week 12 — 72; 31 Participants — p=0.3512
N/A N=89 Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
Spondylitis, Ankylosing
Primary: Percentage of Participants Achieving BASDAI 40 Response at Week 24 — 83.6 Percentage of participants